238 related articles for article (PubMed ID: 26879245)
21. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
22. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
23. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
24. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
25. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
26. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
27. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
Mai E; Zheng Z; Chen Y; Peng J; Severin C; Filvaroff E; Romero M; Mallet W; Kaur S; Gelzleichter T; Nijem I; Merchant M; Young JC
Mol Cancer Ther; 2014 Feb; 13(2):540-52. PubMed ID: 24258345
[TBL] [Abstract][Full Text] [Related]
28. Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.
Pupo E; Ducano N; Lupo B; Vigna E; Avanzato D; Perera T; Trusolino L; Lanzetti L; Comoglio PM
Cancer Res; 2016 Sep; 76(17):5019-29. PubMed ID: 27364553
[TBL] [Abstract][Full Text] [Related]
29. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.
van der Horst EH; Chinn L; Wang M; Velilla T; Tran H; Madrona Y; Lam A; Ji M; Hoey TC; Sato AK
Neoplasia; 2009 Apr; 11(4):355-64. PubMed ID: 19308290
[TBL] [Abstract][Full Text] [Related]
30. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
31. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
32. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.
Vigna E; Chiriaco C; Cignetto S; Fontani L; Basilico C; Petronzelli F; Comoglio PM
Mol Oncol; 2015 Nov; 9(9):1760-72. PubMed ID: 26119717
[TBL] [Abstract][Full Text] [Related]
34. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
[TBL] [Abstract][Full Text] [Related]
35. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
[TBL] [Abstract][Full Text] [Related]
36. Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
Cao B; Su Y; Oskarsson M; Zhao P; Kort EJ; Fisher RJ; Wang LM; Vande Woude GF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7443-8. PubMed ID: 11416216
[TBL] [Abstract][Full Text] [Related]
38. Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.
Yang Y; Mandiyan S; Robinson BS; McMahon G
Cancer Res; 2016 Oct; 76(19):5788-5797. PubMed ID: 27550450
[TBL] [Abstract][Full Text] [Related]
39. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
